Neurocrine Eyes June Launch Date For Valbenazine In Tardive Dyskinesia
Company no longer has to worry about a US FDA advisory committee review, which the agency cancelled. Launch preparations include hiring 140 sales reps.
You may also be interested in...
Neurocrine's US Label For Ingrezza Should Provide Edge Over Teva's Austedo In TD
A summertime battle is expected between Neurocrine and Teva once both companies get their tardive dyskinesia drugs on the US market, but Neurocrine's April 11 approval for Ingrezza without an FDA warning label is already giving the biotech an edge.
Neurocrine Beats Teva To Tardive Dyskinesia Market With Ingrezza
Neurocrine secured FDA approval for the first drug to treat tardive dyskinesia, a large market that crosses multiple diseases and has blockbuster potential.
Teva’s Austedo Positioned To Compete With A Generic Rival
FDA approved Teva’s Austedo (deutetrabenazine) for chorea associated with Huntington’s disease, with a warning on depression and suicidality similar to generic Xenazine, but other parts of the labeling points to advantages.